Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide and ADT in high-risk localized prostate cancer
NCT05249712Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jan 2022
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in prostate cancer (PCa), sponsored by Nanjing Drum-Tower Hospital. Started Jan 2022; status: recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05249712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05249712.